STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
1
13F, latest reported quarter
What the filings say about UROY
Insiders, 180 days
+$43.3K net bought
1 buyer
Activist stakes (13D), 180 days
1 filing
Largest: 7.7% of the class
Uranium Royalty insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Uranium Royalty Corp. insiders bought a net $43.3K of stock across 3 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Canadian issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 0.7% of the 606,048 shares held after it.
No other insider bought within 30 days.
1 fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer MELBYE SCOTT bought about $12.5K of UROY on Jul 30, 2026, the largest insider purchase at the company on our record; 1 fund added in the latest 13F quarter.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 0.7% of the 610,048 shares held after it.
No other insider bought within 30 days.
1 fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer MELBYE SCOTT bought about $12.5K of UROY on Jul 30, 2026, the largest insider purchase at the company on our record; 1 fund added in the latest 13F quarter.
First Form 4 purchase or sale (code P or S) here by this insider on our record.
The trade is 0.9% of the 615,898 shares held after it.
No other insider bought within 30 days.
1 fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer MELBYE SCOTT bought about $18.3K of UROY on Jul 30, 2026, the largest insider purchase at the company on our record; 1 fund added in the latest 13F quarter.
3 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $43.3K bought by insiders over 180 days, 1 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM UROY
FY Apr 2026
n/a
FY Apr 2025
n/a
FY Apr 2024
n/a
FY Apr 2023
n/a
FY Apr 2022
n/a
Jul 2026
$51.0M
Jul 2025
$24.2M
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM UROY
FY Apr 2026
n/a
FY Apr 2025
n/a
FY Apr 2024
n/a
FY Apr 2023
n/a
FY Apr 2022
n/a
Jul 2026
+31.9%
Jul 2025
+4.2%
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM UROY
FY Apr 2026
n/a
FY Apr 2025
n/a
FY Apr 2024
n/a
FY Apr 2023
n/a
FY Apr 2022
n/a
Jul 2026
n/a
Jul 2025
n/a
At each fiscal year end
Single quarter
Debt to equity
0.57x
long-term 2026-07-31 plus current 2026-07-31; equity 2026-07-31
Debt to equity UROY
FY Apr 2026
0.00x
FY Apr 2025
n/a
FY Apr 2024
n/a
FY Apr 2023
n/a
FY Apr 2022
n/a
Jul 2026
0.57x
Jul 2025
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt UROY
FY Apr 2026
n/a
FY Apr 2025
n/a
FY Apr 2024
n/a
FY Apr 2023
n/a
FY Apr 2022
n/a
Jul 2026
n/a
Jul 2025
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on equity UROY
FY Apr 2026
n/a
FY Apr 2025
n/a
FY Apr 2024
n/a
FY Apr 2023
n/a
FY Apr 2022
n/a
Jul 2026
n/a
Jul 2025
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on assets UROY
FY Apr 2026
n/a
FY Apr 2025
n/a
FY Apr 2024
n/a
FY Apr 2023
n/a
FY Apr 2022
n/a
Jul 2026
n/a
Jul 2025
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital UROY
FY Apr 2026
n/a
FY Apr 2025
n/a
FY Apr 2024
n/a
FY Apr 2023
n/a
FY Apr 2022
n/a
Jul 2026
n/a
Jul 2025
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed UROY
FY Apr 2026
n/a
FY Apr 2025
n/a
FY Apr 2024
n/a
FY Apr 2023
n/a
FY Apr 2022
n/a
Jul 2026
n/a
Jul 2025
n/a
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing UROY
FY Apr 2026
n/a
FY Apr 2025
n/a
FY Apr 2024
n/a
FY Apr 2023
n/a
FY Apr 2022
n/a
Jul 2026
n/a
Jul 2025
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.9B
market value at close 2026-10-27 on 2026-09-14 shares, plus long-term 2026-07-31 plus current 2026-07-31, minus cash 2026-07-31
Enterprise value UROY
FY Apr 2026
$279.2M
FY Apr 2025
n/a
FY Apr 2024
n/a
FY Apr 2023
n/a
FY Apr 2022
n/a
Jul 2026
$1.8B
Jul 2025
n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
FCF yield UROY
FY Apr 2026
n/a
FY Apr 2025
n/a
FY Apr 2024
n/a
FY Apr 2023
n/a
FY Apr 2022
n/a
Jul 2026
n/a
Jul 2025
n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing UROY
FY Apr 2026
n/a
FY Apr 2025
n/a
FY Apr 2024
n/a
FY Apr 2023
n/a
FY Apr 2022
n/a
Jul 2026
n/a
Jul 2025
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
UROY ranks highest on growth (99th percentile) and insider conviction (68th), and lowest on financial health (42nd), among Financial Services peers.
Financial health
42
Inputs
Debt to equity0.57x · 42 pct, sector of 181
Cash flow to debtneeds four quarters of operating cash flow
Growth
99
Inputs
Revenue growth, YoY+1566% · 99 pct, sector of 245
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
68
Inputs
Net Form 4 buying (codes P and S), 180d$43K · 80 pct, sector of 160
Insider buyers, 180d1 · 57 pct, sector of 164
Risk and compliance
48
Inputs
Short interest, % of float+3.8% · 48 pct, sector of 388
Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Profitability, Institutional and government, US patents
Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
UROY filings, in plain words
Are Uranium Royalty insiders buying or selling UROY?
In the 180 days to 2026-10-28, Uranium Royalty insiders were net buyers, a net $43.3K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Uranium Royalty insiders were net buyers of UROY, a net $43.3K across purchases and sales reported on Form 4 by 1 buyer. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 7.7% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.